A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_2/print/presentation/3902

Zhen Huang; Zhenyu Zhu; DAOBING ZENG; Shunda Du; Li Jiang; Xu Che; Jinxue Zhou; Dongbin Liu; Jinghai Song; Yubao Zhang; Honggang Qian; Xiaodong Tian; Yongsu Ma

Jul 17, 2026